DK1375512T3 - Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger - Google Patents

Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger

Info

Publication number: DK1375512T3
Authority: DK; Denmark
Prior art keywords: approved; immunogenic compositions; measles virus; vaccine strain; virus vaccine
Prior art date: 2002-06-20

Application number

DK02291551T

Other languages

Danish (da)

English (en)

Inventor

Frederic Tangy

Chantal Combredet

Valerie Labrousse-Najburg

Michel Brahic

Original Assignee

Pasteur Institut

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-20

Filing date

2002-06-20

Publication date

2009-10-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29716946&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1375512(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-06-20 Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut

2009-10-26 Application granted granted Critical

2009-10-26 Publication of DK1375512T3 publication Critical patent/DK1375512T3/da

Links

239000002299 complementary DNA Substances 0.000 title abstract 3
230000002163 immunogen Effects 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
229940124862 Measles virus vaccine Drugs 0.000 title 1
208000015181 infectious disease Diseases 0.000 title 1
230000002458 infectious effect Effects 0.000 title 1
241000712079 Measles morbillivirus Species 0.000 abstract 2
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/165—Mumps or measles virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/12—Mumps virus; Measles virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18441—Use of virus, viral particle or viral elements as a vector
- C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10211—Podoviridae
- C12N2795/10241—Use of virus, viral particle or viral elements as a vector
- C12N2795/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

DK02291551T 2002-06-20 2002-06-20 Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger DK1375512T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP02291551A EP1375512B1 (de)	2002-06-20	2002-06-20	Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen

Publications (1)

Publication Number	Publication Date
DK1375512T3 true DK1375512T3 (da)	2009-10-26

Family

ID=29716946

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK02291551T DK1375512T3 (da)	2002-06-20	2002-06-20	Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger
DK10184511.3T DK2311853T3 (en)	2002-06-20	2003-06-20	Infectious cDNA of an approved measles virus vaccine strain. Use for immunogenic compositions

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK10184511.3T DK2311853T3 (en)	2002-06-20	2003-06-20	Infectious cDNA of an approved measles virus vaccine strain. Use for immunogenic compositions

Country Status (15)

Country	Link
US (3)	US9005961B2 (de)
EP (5)	EP1375512B1 (de)
KR (1)	KR101227128B1 (de)
CN (1)	CN100577683C (de)
AT (1)	ATE437175T1 (de)
AU (1)	AU2003266950A1 (de)
BR (1)	BRPI0312173B8 (de)
CA (1)	CA2489052C (de)
CY (1)	CY1109506T1 (de)
DE (1)	DE60233038D1 (de)
DK (2)	DK1375512T3 (de)
ES (2)	ES2330309T3 (de)
HK (1)	HK1061568A1 (de)
PT (1)	PT1375512E (de)
WO (1)	WO2004000876A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1201750A1 (de) *	2000-10-26	2002-05-02	Genopoietic	Synthetische Viren und ihre Verwendungen
EP1375512B1 (de)	2002-06-20	2009-07-22	Institut Pasteur	Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
ES2427139T3 (es)	2002-06-20	2013-10-29	Institut Pasteur	Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
CA2432738A1 (en)	2003-02-26	2004-08-26	Philippe Despres	New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
US20090004203A1 (en) *	2007-05-29	2009-01-01	Vical Incorporated	Methods of treating measles infectious disease in mammals
US8673315B2 (en) *	2007-11-26	2014-03-18	London School Of Hygiene & Tropical Medicine	Method for producing vaccinal viral strain of a virus of the reoviridae family
EP2085479A1 (de) *	2008-01-31	2009-08-05	Institut Pasteur	Reverse Genetik von Negativstrang-RNA-Viren in Hefe
EP2420242A1 (de)	2010-08-20	2012-02-22	Lauer, Ulrich M.	Onkolytisches Masernvirus
EP2780034A1 (de)	2011-11-14	2014-09-24	Crucell Holland B.V.	Heterologe prime-boost-impfung mit auf masernviren basierten impfstoffen
EP2712871A1 (de) *	2012-09-27	2014-04-02	Institut Pasteur	Rekombinantes Masernvirus zur Expression von Chikungunya-Virus-Polypeptiden und deren Anwendungen
EP2759301A1 (de)	2013-01-24	2014-07-30	Institut Pasteur	Verwendung eines genetisch modifizierten infektiösen Masernvirus mit erhöhten pro-apoptotischen Eigenschaften (MVDeltaC-Virus)
WO2015092710A1 (en)	2013-12-19	2015-06-25	Glaxosmithkline Biologicals, S.A.	Contralateral co-administration of vaccines
EP2959915A1 (de)	2014-06-23	2015-12-30	Institut Pasteur	Chimäres Dengue-Virus-Polyepitop aus Fragmenten nichtstruktureller Proteine und deren Verbindung in einer immunogenen Zusammensetzung gegen Dengue-Virus-Infektion
EP3103474A1 (de) *	2015-06-12	2016-12-14	Institut Pasteur	Lebendes rekombinantes masern-m2-virus und dessen verwendung bei auslösung von immunität gegen influenzaviren
EP3184119A1 (de)	2015-12-23	2017-06-28	Themis Bioscience GmbH	Chromatografiebasierte reinigungsstrategien für viren auf basis eines maserngerüsts
JP6949468B2 (ja) *	2016-10-17	2021-10-13	ルプレヒト−カールス−ウニベルジテートハイデルベルク	腫瘍抗原をコードする麻疹ウイルス
WO2018206512A1 (en) *	2017-05-09	2018-11-15	Invectys	Recombinant measles vaccine expressing htert
EP3412307A1 (de)	2017-06-07	2018-12-12	Institut Pasteur	Zika-virus-proteine zur expression eines rekombinanten masernvirus und deren anwendungen
BR112020009157A2 (pt)	2017-11-09	2020-10-27	Institut Pasteur	poliepítopo quimérico, polinucleotídeo, vetor, célula hospedeira e composição imunogênica
US11976305B2 (en) *	2017-12-21	2024-05-07	Institut Pasteur	Lassa vaccine
CN111218475A (zh) *	2018-11-23	2020-06-02	成都生物制品研究所有限责任公司	一种拯救麻疹Schwarz/Moraten疫苗株的***和方法
EP3865180A1 (de) *	2020-02-13	2021-08-18	Institut Pasteur	Lebende rekombinante masernviren, die coronavirus-antigene exprimieren, verwendung davon zur erzeugung von immunität gegen coronaviren
CA3166811A1 (en) *	2020-02-13	2021-08-19	Nicolas Robert Xavier Escriou	Measles-vectored covid-19 immunogenic compositions and vaccines
EP3936517A1 (de)	2020-07-08	2022-01-12	Institut Pasteur	Verbesserter masernvirusimpfstoffvektor basierend auf mehreren zusätzlichen tandemtranskriptionseinheiten
CA3204201A1 (en)	2021-01-13	2022-07-21	Thierry Heidmann	Measles-hiv or measles-htlv vaccine
CN113293148B (zh) *	2021-03-10	2022-10-25	上海青赛生物科技有限公司	一种h基因替换的嵌合麻疹减毒株的构建
WO2022195900A1 (ja) *	2021-03-15	2022-09-22	国立大学法人東京大学	組換え麻疹ウイルス

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7007491A (en)	1990-02-02	1991-08-08	Schweiz. Serum- & Impfinstitut Bern	Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
JP3045581B2 (ja) *	1991-10-14	2000-05-29	社団法人北里研究所	麻疹ワクチンウイルス株同定方法
DE69510207T3 (de) *	1995-08-09	2007-02-15	Schweiz. Serum- & Impfinstitut Bern	Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
CN1232504A (zh) *	1996-09-27	1999-10-20	美国氰胺公司	在单链负义病毒目病毒内引起减毒的3'基因组启动子区和聚合酶基因中的突变
ES2345614T3 (es)	1997-02-28	2010-09-28	Sanofi Pasteur Biologics Co.	Vacunas quimericas de flavivirus.
BRPI9701774B8 (pt) *	1997-04-11	2015-09-29	Fundação Oswaldo Cruz Fiocruz	cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6410023B1 (en) *	1997-05-23	2002-06-25	United States Of America	Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
CN1600852A (zh) *	1998-03-26	2005-03-30	惠氏控股有限公司	引起麻疹病毒或人呼吸道合胞病毒亚组b减毒的突变
WO1999063064A1 (en) *	1998-06-03	1999-12-09	American Cyanamid Company	Novel methods for rescue of rna viruses
US6146642A (en) *	1998-09-14	2000-11-14	Mount Sinai School Of Medicine, Of The City University Of New York	Recombinant new castle disease virus RNA expression systems and vaccines
EP1218499A2 (de)	1999-08-02	2002-07-03	Wyeth	Rückgewinnung von mumps virus aus cdns
US6951754B2 (en) *	2000-04-28	2005-10-04	St. Jude Children's Research Hospital	DNA transfection system for the generation of infectious influenza virus
EP1375512B1 (de) *	2002-06-20	2009-07-22	Institut Pasteur	Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
ES2427139T3 (es) *	2002-06-20	2013-10-29	Institut Pasteur	Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
CA2432738A1 (en)	2003-02-26	2004-08-26	Philippe Despres	New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
CA2508266A1 (fr)	2005-06-20	2006-12-20	Institut Pasteur	Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
EP1939214B1 (de)	2006-12-22	2013-07-10	Institut Pasteur	Zellen und Methoden zur Generierung von Nichtsegmentierter Negativ-Strang-RNA-Viren
JP5726727B2 (ja) *	2008-05-26	2015-06-03	カディラ・ヘルスケア・リミテッド	麻疹−ヒトパピローマ混合ワクチン
KR20140070659A (ko) *	2009-05-05	2014-06-10	카딜라 핼쓰캐어 리미티드	홍역-말라리아 조합 백신

2002
- 2002-06-20 EP EP02291551A patent/EP1375512B1/de not_active Expired - Lifetime
- 2002-06-20 DK DK02291551T patent/DK1375512T3/da active
- 2002-06-20 EP EP09165802A patent/EP2110382A1/de not_active Withdrawn
- 2002-06-20 DE DE60233038T patent/DE60233038D1/de not_active Expired - Lifetime
- 2002-06-20 ES ES02291551T patent/ES2330309T3/es not_active Expired - Lifetime
- 2002-06-20 AT AT02291551T patent/ATE437175T1/de active
- 2002-06-20 PT PT02291551T patent/PT1375512E/pt unknown
2003
- 2003-06-20 EP EP08169719A patent/EP2065393A1/de not_active Withdrawn
- 2003-06-20 EP EP03747858A patent/EP1513872A1/de not_active Ceased
- 2003-06-20 DK DK10184511.3T patent/DK2311853T3/en active
- 2003-06-20 CN CN03814471A patent/CN100577683C/zh not_active Expired - Lifetime
- 2003-06-20 KR KR1020047020803A patent/KR101227128B1/ko active IP Right Grant
- 2003-06-20 BR BRPI0312173A patent/BRPI0312173B8/pt active IP Right Grant
- 2003-06-20 WO PCT/EP2003/007145 patent/WO2004000876A1/en not_active Application Discontinuation
- 2003-06-20 EP EP10184511.3A patent/EP2311853B1/de not_active Expired - Lifetime
- 2003-06-20 CA CA2489052A patent/CA2489052C/en not_active Expired - Lifetime
- 2003-06-20 ES ES10184511.3T patent/ES2663224T3/es not_active Expired - Lifetime
- 2003-06-20 AU AU2003266950A patent/AU2003266950A1/en not_active Abandoned
2004
- 2004-06-16 HK HK04104400.2A patent/HK1061568A1/xx not_active IP Right Cessation
- 2004-12-17 US US11/013,786 patent/US9005961B2/en active Active
2008
- 2008-07-24 US US12/219,570 patent/US9005925B2/en active Active
2009
- 2009-09-18 CY CY20091100970T patent/CY1109506T1/el unknown
2015
- 2015-03-24 US US14/667,088 patent/US9701944B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
BRPI0312173B1 (pt)	2019-05-07
EP1375512A1 (de)	2004-01-02
CY1109506T1 (el)	2014-08-13
DE60233038D1 (de)	2009-09-03
HK1061568A1 (en)	2004-09-24
KR101227128B1 (ko)	2013-01-29
EP1513872A1 (de)	2005-03-16
CA2489052C (en)	2014-07-29
US9005925B2 (en)	2015-04-14
US20130296541A1 (en)	2013-11-07
US20050227224A1 (en)	2005-10-13
AU2003266950A8 (en)	2004-01-06
EP2065393A1 (de)	2009-06-03
EP2110382A1 (de)	2009-10-21
ATE437175T1 (de)	2009-08-15
ES2663224T3 (es)	2018-04-11
AU2003266950A1 (en)	2004-01-06
ES2330309T3 (es)	2009-12-09
BR0312173A (pt)	2005-04-05
CN100577683C (zh)	2010-01-06
BRPI0312173B8 (pt)	2021-05-25
US9005961B2 (en)	2015-04-14
US20150275184A1 (en)	2015-10-01
KR20050058288A (ko)	2005-06-16
CN1662553A (zh)	2005-08-31
CA2489052A1 (en)	2003-12-31
US9701944B2 (en)	2017-07-11
PT1375512E (pt)	2009-09-23
DK2311853T3 (en)	2018-04-16
EP1375512B1 (de)	2009-07-22
EP2311853A1 (de)	2011-04-20
EP2311853B1 (de)	2017-12-27
WO2004000876A1 (en)	2003-12-31
WO2004000876A8 (en)	2005-03-03

Publication	Publication Date	Title
DK1375512T3 (da)	2009-10-26	Infektiös cDNA af en godkendt vaccinestamme af mæslingevirus. Anvendelse til immunogene sammensætninger
EA200501890A1 (ru)	2006-06-30	Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
ATE491471T1 (de)	2011-01-15	Adjuvantien für dns impstoffe basierend auf imidazochinoline
DK1211318T3 (da)	2007-11-12	Paramyxovira omfattende en modificeret transkriptionsstartsekvens
DK0702085T3 (da)	2004-04-19	Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
CY1107146T1 (el)	2012-05-23	Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
ATE527281T1 (de)	2011-10-15	Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
DK1086207T3 (da)	2007-05-29	Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira
MA30581B1 (fr)	2009-07-01	Vaccin viral recombinant
EA200870237A1 (ru)	2009-06-30	Последовательности пептидов и композиции
WO2009026465A3 (en)	2009-04-09	Composition and methods of making and using influenza proteins
ATE419369T1 (de)	2009-01-15	Chimäre mensch-rinder respiratory syncytial virus vakzinen
ATE521621T1 (de)	2011-09-15	Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
DK1831239T3 (da)	2010-06-28	Fremgangsmåde til fremstilling af 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-carboxylsyre-lambda-lacton og nøgle-mellemprodukter til denne fremgangsmåde
BRPI0408895A (pt)	2006-04-11	formulações de cladribina para administração oral e transmucosal aperfeiçoada
DK1356822T3 (da)	2011-02-07	Farmaceutiske sammensætninger, der forøger immunogeniteten af svagt immunogene antigener
ATE420191T1 (de)	2009-01-15	Promotoren zur expression im modifizierten vacciniavirus ankara
WO2005011571A3 (en)	2006-01-05	Hepatitis virus core proteins as vaccine platforms and methods of use thereof
DE60040219D1 (de)	2008-10-23	Infektiöses cdna klon des gb-virus b und dessen verwendungen
ATE420658T1 (de)	2009-01-15	Imidazoquinolinamine als adjuvantien für hiv dna vakzine
FR2829498B1 (fr)	2003-11-28	Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
DK1602360T3 (da)	2012-02-13	Fremgangsmåde til opnåelse af sneglestrukturer, vaccinesammensætninger, adjuvanser og mellemprodukter dertil
DK1383796T3 (da)	2009-08-17	Neurovirulent stamme af viruset West Nile og anvendelser heraf
ATE447008T1 (de)	2009-11-15	Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon
MX2019014819A (es)	2021-06-10	Plásmido para inserción simplificada de secuencias cortas de adn en un cistrón que codifica para una proteína de cápside potyviral y método de aplicación.